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Colorectal cancer (CRC) is the third most frequent neoplastic disorder and is a main cause
of tumor-related mortality, as many patients progress to stage IV metastatic CRC. Standard
care consists of combination chemotherapy (FOLFIRI or FOLFOX). Patients with WT KRAS
typing are eligible to receive anti-EGFR therapy combined with chemotherapy.
Unfortunately, predicting efficacy of CRC anti-EGFR therapy has remained challenging.
Here we uncovered that the EGFR pathway component RasGRP1 acts as a CRC tumor
suppressor in the context of aberrant Wnt signaling. We found that RasGRP1 suppresses
EGF-driven proliferation of colonic epithelial organoids. Having established that RasGRP1
dosage levels impact biology, we next focused on CRC patients. Mining 5 different data
platforms, we establish that RasGRP1 expression levels decrease with CRC progression
and predict poor clinical outcome of patients. Last, deletion of 1 or 2 Rasgrp1 alleles made
CRC spheroids more susceptible to EGFR inhibition. Retrospective analysis of the CALGB
80203 clinical trial showed that addition of anti-EGFR therapy to chemotherapy significantly
improved outcome for CRC patients when tumors expressed low levels of RasGRP1
suppressor. In sum, our data support RasGRP1 as a biomarker in the EGFR pathway that
has potential relevance to anti-EGFR therapy for CRC patients.
Research Article Gastroenterology Therapeutics
Find the latest version:
http://jci.me/127552/pdf
1insight.jci.org   https://doi.org/10.1172/jci.insight.127552
R E S E A R C H  A R T I C L E
Authorship note: CB, DG, and CYW 
contributed equally to this work. JPR 
and PD are co–senior authors.
Conflict of interest: PD, RSW, and 
JPR are holders of the patent PCT/
US2016/025334, Prognostic and 
Diagnostic Methods for Colorectal 
Cancer. OMG, PD, RSW, and JPR hold 
stock in SealBiosciences Inc.
Copyright: © 2019, American Society 
for Clinical Investigation.
Submitted: January 23, 2019 
Accepted: June 19, 2019 
Published: August 8, 2019.
Reference information: JCI Insight. 
2019;4(15):e127552. https://doi.
org/10.1172/jci.insight.127552.
RasGRP1 is a potential biomarker for 
stratifying anti-EGFR therapy response in 
colorectal cancer
Oghenekevwe M. Gbenedio,1 Caroline Bonnans,1,2 Delphine Grun,3 Chih-Yang Wang,1 Ace J. Hatch,4 
Michelle R. Mahoney,5 David Barras,3 Mary Matli,6 Yi Miao,7 K. Christopher Garcia,7 Sabine Tejpar,2 
Mauro Delorenzi,3,8 Alan P. Venook,9 Andrew B. Nixon,5 Robert S. Warren,6 Jeroen P. Roose,1  
and Philippe Depeille1
1Department of Anatomy, UCSF, San Francisco, California, USA. 2Institut National de la Santé et de la Recherche Médicale, 
Montpellier, France. 3Bioinformatics Core Facility (BCF) at SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland. 
4Department of Medicine, Duke University, Durham, North Carolina, USA. 5Alliance Statistics and Data Center, Mayo Clinic, 
Rochester, Minnesota, USA. 6Department of Surgery, UCSF, San Francisco, California, USA. 7Department of Molecular 
and Cellular Physiology, Department of Structural Biology and Howard Hughes Medical Institute, Stanford University 
School of Medicine, Stanford, California, USA. 8Department of Oncology, University of Lausanne, Lausanne, Switzerland. 
9Hematology/Oncology, Department of Medicine, UCSF, San Francisco, California, USA.
Introduction
Colorectal cancer (CRC) represents the third most frequent neoplastic disorder worldwide and one of  the 
main causes of  tumor-related mortality (1). Combination chemotherapy, such as FOLFIRI (leucovorin, flu-
orouracil, and irinotecan) and FOLFOX (leucovorin, fluorouracil, and oxaliplatin), has become the main 
treatment option for patients with CRC (2, 3). Thirty-five percent of  CRC patients are diagnosed at stage IV 
metastatic CRC, and a large proportion of  stage II and III CRC patients progress to stage IV at some point 
during their course of  disease (4). Unfortunately, the 5-year survival rate for stage IV metastatic CRC patients 
is only approximately 13% (https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-stag-
ing/survival-rates.html). EGFR expression is widespread in CRC (5). Use of  targeted therapies that inhibit 
the action of  the EGFR — such as cetuximab, an antibody that binds and interferes with the EGFR — have 
been approved in combination with chemotherapy for metastatic CRC (6). Multiple randomized trials includ-
ing both chemorefractory and chemonaive patients with metastatic CRC have established the overall survival 
(OS) benefits of  the anti-EGFR blocking antibodies cetuximab and panitumumab (5). Examples are the Can-
cer and Leukemia Group B (CALGB; now part of  Alliance for Clinical Trials in Oncology) 80203 trial with 
metastatic CRC patients on FOLFIRI/FOLFOX therapy, which was closed early (7); and the CALGB 80405 
trial, which compares FOLFIRI/FOLFOX therapy with bevacizumab (anti-VEGF) or with cetuximab.
Colorectal cancer (CRC) is the third most frequent neoplastic disorder and is a main cause of tumor-
related mortality, as many patients progress to stage IV metastatic CRC. Standard care consists 
of combination chemotherapy (FOLFIRI or FOLFOX). Patients with WT KRAS typing are eligible 
to receive anti-EGFR therapy combined with chemotherapy. Unfortunately, predicting efficacy 
of CRC anti-EGFR therapy has remained challenging. Here we uncovered that the EGFR pathway 
component RasGRP1 acts as a CRC tumor suppressor in the context of aberrant Wnt signaling. 
We found that RasGRP1 suppresses EGF-driven proliferation of colonic epithelial organoids. 
Having established that RasGRP1 dosage levels impact biology, we next focused on CRC patients. 
Mining 5 different data platforms, we establish that RasGRP1 expression levels decrease with CRC 
progression and predict poor clinical outcome of patients. Last, deletion of 1 or 2 Rasgrp1 alleles 
made CRC spheroids more susceptible to EGFR inhibition. Retrospective analysis of the CALGB 
80203 clinical trial showed that addition of anti-EGFR therapy to chemotherapy significantly 
improved outcome for CRC patients when tumors expressed low levels of RasGRP1 suppressor. In 
sum, our data support RasGRP1 as a biomarker in the EGFR pathway that has potential relevance to 
anti-EGFR therapy for CRC patients.
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Nonetheless, it has been challenging to predict success with these antibodies or with EGFR kinase 
inhibitors (erlotinib) in CRC. After introduction of  cetuximab and panitumumab into the clinic, evidence 
soon arose that tumors harboring activating mutations in KRAS are insensitive to EGFR inhibition. Somat-
ic mutations in KRAS (8, 9) occur in roughly 40% of  CRC patients (10), and these mutations in KRAS have 
also been implicated as mediators of  acquired resistance to anti-EGFR therapy (11, 12). Furthermore, 
roughly 40% of  CRC patients reveal mutations in NRAS (13). These notions led to systematic, FDA-ap-
proved typing for RAS as an accompanying diagnostic, and since 2012 anti-EGFR therapy has been 
restricted to patients without detectible KRAS and NRAS mutations (5). Still, there remain significant gaps 
between available analytical tools used to assess therapeutic benefit or risk, the likelihood of  response or 
progression, and actual patient clinical outcome, and it is clear that KRAS and NRAS status are not the only 
determinants. Further, anti-EGFR therapy is costly and can be toxic; thus, the need to better understand the 
role of  EGFR signals in CRC and to identify additional predictive markers is clear.
In the intestine, Wnt ligands signal to ensure self-renewal of  stem cells in the crypt regions that pro-
duce daughter cells (14). Wnt signals support stem cell function in many organs and enable the genera-
tion of  organoids that can be perpetuated in Matrigel in vitro (15, 16). Binding of  the ligand R-spondin 
to the receptor leucine-rich repeat-containing receptor 5 (Lgr5) enables sustained Wnt signals (17), and 
R-spondin and surrogate Wnt ligands are highly effective in sustaining the growth of  organoids (18). Stem 
and progenitor cells in the intestine are also exposed to EGFR signals (14), and Ras/MAPK signals are 
observed in human progenitor cells in normal intestinal crypts as well (19). Deletion of  Egfr in mice leads 
to disorganized crypts (20), and fine-tuning of  EGFR signaling is critical for balanced proliferation in the 
intestinal stem cell niche (21, 22). Deletion of  KRas has no effect on the adult intestinal epithelium in mice 
(23), but expression of  an oncogenic form of  KRas, KRasG12D, in the murine colonic epithelium leads to 
hyperproliferation in a Ras/MAP kinase–dependent manner (24). The above-mentioned studies imply that 
EGFR/Ras signals balance proliferation and differentiation in intestinal progenitor cells (19, 21, 22). Better 
understanding of  how EGFR/Ras signaling nuances impact CRC and particularly responses to anti-EGFR 
therapy could improve the clinical use of  EGFR-targeting agents.
The EGFR couples to Ras guanine nucleotide exchange factors (RasGEFs) that can activate the small 
GTPase Ras (25). We previously established that 2 RasGEFs, RasGRP1 and SOS1, are structurally and 
biochemically different (26–29). Both RasGRP1 and SOS lie downstream of  the EGFR (30), and we 
demonstrated that these RasGEFs play opposing roles in the intestine. Whereas SOS1 stimulates prolif-
eration of  cancer cells (30, 31), RasGRP1 opposes EGFR/SOS1 signals and thus suppresses proliferation 
(30). Rasgrp1 deficiency results in hyperproliferation of  nontransformed intestinal epithelial cells and leads 
to exacerbation of  CRC when this epithelium also carries oncogenic mutations in KRas or adenomatous 
polyposis coli (APC) (30, 32, 33). Here, we established that RasGRP1 functions as a tumor suppressor in the 
colon and suppresses EGF-driven proliferation of  colonic organoid cultures. Decreases in RasGRP1 levels 
were prognostic of  poor clinical outcome for CRC patients. Last, spheroid assays and clinical trial data 
revealed that RasGRP1 expression levels predicted efficacy of  anti-EGFR therapy in CRC.
Results
RasGRP1 is a tumor suppressor in the colonic epithelium of  ApcMin/+ mice. Given that RasGRP1 opposes prolif-
erative EGFR/SOS1 signals in CRC (30), we performed a more detailed analysis of  the expression levels 
of  RasGRP1 and tested our hypothesis that deletion of  only 1 Rasgrp1 allele may have a biological impact.
We first mined published gene expression data deposited in the Gene Expression Omnibus database 
(GEO GSE49355) on sets of  trio samples from individual patients with advanced CRC receiving FOLFIRI 
(34). This platform revealed that the levels of  RasGRP1 expression in epithelium from the same patient was 
lower in primary CRC compared with normal tissue. There was an additional decrease in RasGRP1 expres-
sion when primary CRC and CRC metastasis was compared in the liver (Figure 1A), suggesting that levels 
of  RasGRP1 could play a role in CRC progression.
We next determined Rasgrp1 expression levels along 5 segments of  the intestinal track in the mouse 
(Figure 1B). We utilized intestine from Rag1-deficient mice, which do not have T or B cells, in order to 
avoid potential sample contamination with these lymphocyte subsets that express high levels of  Rasgrp1 
(35). We observed that Rasgrp1 protein levels were highest in the duodenum and more moderate in the oth-
er parts along the intestinal track (Figure 1C and Supplemental Figure 1; supplemental material available 
online with this article; https://doi.org/10.1172/jci.insight.127552DS1), a pattern that was mirrored by 
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Rasgrp1 mRNA expression data (Figure 1D). By contrast, mRNA expression levels of  the RasGEF Sos1, 
proproliferative in its function (30, 31), were similar throughout the intestinal track (Figure 1E).
In mouse models, heterozygosity for Rasgrp1 results in roughly half  the Rasgrp1 protein expression 
(36). To test the implications of  reduced levels of  RasGRP1 expression in the context of  CRC, we capital-
ized on the ApcMin/+ mouse model with aberrant Wnt signaling (37), which is widely used to mimic human 
CRC (38–40). Complete deficiency in Rasgrp1 results in reduced survival of  ApcMin/+ mice due to increased 
EGFR/SOS1 signals driving proliferation (30). Here, we uncovered that Rasgrp1 had stereotypical features 
of  a tumor suppressor; ApcMin/+ mice died earlier from disease when they harbored only 1 allele of  Rasgrp1 
(Figure 1F and Supplemental Figure 2A). ApcMin/+ mice develop frequent tumors in the small intestine but 
rarely in the colon (38–40), a limitation of  this murine model for human CRC. Deficiency or heterozygos-
ity for Rasgrp1 in the context of  ApcMin/+ did not result in altered numbers or size of  small intestine tumors 
(Supplemental Figure 2B and ref. 30); instead there was an effect on the colon. Strikingly, there was a 
prominent increase in the frequency of  tumors in the distal part of  the colon when Rasgrp1 was deleted 
(Figure 1, G and H). Individual tumors heterozygous for Rasgrp1 grew to a larger size before we had to 
euthanize ApcMin/+:Rasgrp1WT/– mice, while the absolute number of  tumors was not different from that in 
ApcMin/+ mice (Figure 1I and Supplemental Figure 2C). It should be noted the that tumor data in Figure 
1, G–I, and Supplemental Figure 2C originated from mice of  different ages and that we had to euthanize 
ApcMin/+:Rasgrp1WT/– and ApcMin/+:Rasgrp1–/– mice at an earlier age. Of  note, the effects on colonic tumors 
were not caused by T cell defects; first, Rasgrp1WT/– have normal T cell development (41), and second, when 
we grafted ApcMin/+:Rasgrp1–/– mice with ApcMin/+ bone marrow to circumvent the known T cell deficiency in 
Rasgrp1–/– mice (41), we also observed colonic tumors (Supplemental Figure 3). In sum, these results reveal 
that Rasgrp1 is a tumor suppressor gene in colonic epithelium with aberrant Wnt signaling.
Rasgrp1 suppresses EGFR-driven growth of  colonic organoids. The features of  increased number and size of  
colonic tumors in ApcMin/+ mice caused by decreases in Rasgrp1 alleles are similar to those of  ApcMin/+ mice 
with deletion of  leucine-rich repeats and Ig-like domains 1 (Lrig1) (22). Lrig1 is a transmembrane mole-
cule and an intestinal stem cell marker (22). Tet-induced expression of  Lrig1 provides negative feedback to 
EGFR signaling (42) to balance intestinal stem cell homeostasis (21). Because of  these similarities, we next 
investigated the functional impact of  Rasgrp1 deletion in the normal colonic epithelium by optimizing the 
generation of  colonic epithelial organoids (Figure 2A).
Colonic epithelial organoids were originally described by Sato et al. (43). We capitalized on R-spondin 
and Wnt surrogate ligands that trigger Lgr5 and LRP/Frizzled receptors to phenocopy sustained, canon-
ical Wnt signaling (ref. 18 and Figure 2B). These Rspo-Wnt ligands allowed for efficient generation of  
colonic epithelium organoids (termed colonic organoids herein) from both young WT and young Rasgrp1–/– 
mice (Figure 2C). WT and Rasgrp1–/– colonic organoids revealed similar Egfr and Sos1 expression levels 
(Figure 2D). Rasgrp1–/– colonic organoids proliferated more vigorously than WT counterparts in Rspo-Wnt 
surrogate–supplemented Matrigel (Figure 2E). We subsequently analyzed growth of  organoids on day 3, a 
time point of  exponential growth phase. The growth rate was drastically reduced in both WT and Rasgrp1–/– 
organoids when these were subjected to the EGFR kinase inhibitor erlotinib (Figure 2F), which supports 
the hypothesis that proliferation is EGFR signaling dependent. In sum, Rasgrp1 limited proliferation of  
colonic organoids and organoid proliferation required uninhibited EGFR signaling.
RasGRP1 is a prognostic marker for clinical outcome of  CRC. Given our findings on Rasgrp1’s role in mouse 
colonic organoids, we next explored RasGRP1 expression relative to clinical outcome in samples from 
CRC patients using 4 different platforms.
We first interrogated the Cancer Genome Atlas (TCGA). Mutations in APC, the tumor suppressor P53, 
and KRAS are the 3 most frequent genetic events leading to CRC (44). Using TCGA data, we found that 
RasGRP1 expression levels were lower in patients with mutations in the APC or TP53 tumor suppressors 
when compared with patients with WT APC or P53 alleles in their tumors (Figure 3, A and B). We did not 
observe a significant difference in RasGRP1 expression when tumors were stratified solely based on KRAS 
status (Figure 3C). However, in agreement with the pattern of  decreasing RasGRP1 expression when CRC 
advanced (Figure 1A), we observed progressively lower RasGRP1 levels when tumors accumulated more 
mutations in the 3 main drivers, APC, P53, and KRAS (Figure 3D). By contrast, SOS1 expression levels were 
not altered as a function of  mutational load for APC, P53, or KRAS (Figure 3E).
Second, we capitalized on our own collection of  resected, biobanked liver metastases from patients 
with stage IV CRC to establish that there is a range of  RasGRP1 mRNA expression in tumor samples that 
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Figure 1. RasGRP1 acts as a tumor suppressor in ApcMin mice. (A) Normalized RasGRP1 mRNA levels analyzed with GeneSpring GX software. Normal colon 
(n = 18), primary colonic tumor (n = 20) and liver metastasis (n = 19). One-way ANOVA statistical analysis with Bonferroni corrections was carried out using 
SPSS 17.0. Post hoc t tests using SPSS Bonferroni-adjusted P values. Box and whisker plots indicate the median value and upper- and lower- quartiles in 
the box and the upper- and lower- extremes in the whiskers. (B and C) Detection of Rasgrp1 expression by Western blot analysis in different sections of 
small intestine (duodenum, 1; jejunum, 2; and ileum, 3) and colon (proximal, 4; and distal, 5). The Western blot is a representative example of 3 inde-
pendent experiments. β-Actin served as protein loading control. Protein lysate from CD4-positive mouse cells (C57BL/6; mCD4+ T) was used as positive 
control for Rasgrp1. Western blots from 2 more extraction are shown in Supplemental Figure 1. Rasgrp1 (D) and Sos1 (E) mRNA levels determined by 
TaqMan PCR on distinct portions of the intestinal tract. mRNA expression for one duodenum portion was used as an arbitrary reference and set at 1.0, and 
other samples values were related to it. Data are presented as fold difference compared with the value of 1.0 in duodenum and plotted from n = 3 inde-
pendent experiments (n = 3 mice). Each point represents an average of 2 wells. **P < 0.001 (1-way ANOVA, Bonferroni’s multiple-comparisons test). (F) 
Kaplan-Meier curves of ApcMin/+ mouse survival with different copies of Rasgrp1 alleles. Statistical analysis was performed on ApcMin/+:Rasgrp1WT/– (n = 37) 
and compared with ApcMin/+ mice (n = 25). *P < 0.05, log-rank (Mantel-Cox) test, which means that the 2 groups are significantly different from each other. 
(G) Quantification of colonic tumor incidence in ApcMin/+, ApcMin/+:Rasgrp1WT/–, and ApcMin/+:Rasgrp1–/– mice (n = 16, 25, and 19, respectively; **P < 0.05, *** 
P < 0.001 (1-way ANOVA, Bonferroni’s multiple-comparisons test). One dot represents one mouse. (H) Distal colon of an ApcMin/+:Rasgrp1–/– mouse bearing 
colonic adenomas. (I) Percentages of colonic tumors of the indicated sizes in ApcMin/+, ApcMin/+:Rasgrp1WT/– and ApcMin/+:Rasgrp1–/– mice (n = 10, 15, and 19, 
respectively). Additional data are shown in Supplemental Figure 2C.
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Figure 2. RasGRP1 is a critical suppressor of EGF-induced growth in the colon. (A) Pipeline of colonic organoid generation. (B) Schematic representa-
tion of Wnt surrogate ligands simultaneously triggering LDL receptor-related protein 5 and 6 (LRP5/6) and Frizzled (FZD) as well as R-spondin (RSPO) 
contributing to sustained, canonical Wnt signaling. (C) Colonic organoids from individual WT and Rasgrp1–/– mice. Each image is a representative example 
of 12 wells of organoids per genotype from 3 independent experiments (n = 3 mice per genotype; n = 9 total). Scale bars: 200 μm. (D). Detection of Egfr and 
Sos1 expression by Western blot analysis in growing organoids from WT and Rasgrp1–/– mice (n = 2 mice per genotype). β-Actin served as protein loading 
control. Panels are representative of 2 independent organoid experiments. (E) Proliferation of developing organoids (represented in C) evaluated in growth 
media containing R-spondin and Wnt surrogate ligand over 5 days. Each point represents the average of 2 wells in triplicate (n = 3 mice per genotype). (F) 
Organoids were treated with erlotinib at different doses (0.2, 0.5, 2 μM) for 1, 3, and 5 days. All values were normalized to untreated on similar developing 
day. Data are representative of 3 independent experiments (n = 3 mice per genotype) with 2 wells per condition. We analyzed growth of organoids on day 
3, when these were in the exponential growth phase. *P < 0.05, **P < 0.01, ****P < 0.01, NS not significant (1-way ANOVA, Bonferroni’s multiple-compari-
sons test). Data are mean ± SEM.
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presents itself  in a continuum, for both KRASWT and KRASMUT tumors (Figure 3F). By and large, the levels 
of  RasGRP1 protein, determined by immunohistochemistry with a RasGRP1-specific monoclonal anti-
body (Figure 3G), paralleled the mRNA levels.
Third, to assess whether RasGRP1 levels may have prognostic value for clinical outcome of  CRC, we 
first explored the correlation between RasGRP1 expression and survival of  752 CRC patients who were 
enrolled in the Pan-European Trial in Adjuvant Colon Cancer 3 (PETACC-3) trial. The PETACC-3 trial 
(45) includes stage II and III patients and was designed to investigate whether disease-free status improved 
when irinotecan was added as adjuvant to infusional 5-fluorouracil/leucovorin (FU/LV) combination. 
Instead of  applying more commonly used cutoff  finder software, we divided the 752 patients without any 
bias into exact 50/50 groups (RasGRP1hi and RasGRP1lo) based solely on the RasGRP1 expression level 
in their tumors, as determined by using the ALMAC Colorectal Cancer DSA platform (45, 46). We next 
correlated RasGRP1hi and RasGRP1lo to overall survival. This unbiased 50/50 split revealed that RasGRP1 
had prognostic value as a single marker on 282 stage II and III patients with KRASmut, with the 141 RasGR-
P1hi patients showing significantly prolonged survival (Figure 3H). When all 752 stage II and III patients 
were analyzed in one group, RasGRP1 did not have prognostic value as a single marker (Supplemental 
Figure 4). Dividing patients in SOS1hi/SOS1lo groups did not correlate with survival, irrespective of  KRAS 
status of  the tumor (Supplemental Figure 4).
Various features of  CRC have been described to correlate with clinical outcome. One of  these is micro-
satellite stability or instability. Microsatellite instability (MSI) generally correlates with better clinical out-
come (47, 48), and in agreement with this notion, we observed better clinical outcome in the 75 PETACC-3 
patients who demonstrated MSI (Supplemental Figure 5A). On average, these 75 MSI-positive PETACC-3 
patients had higher RasGRP1 levels than the 603 patients with microsatellite stability (MSS) (Supplemental 
Figure 5B). Combining both RasGRP1 expression and MSI or MSS for the patient group analyzed in Fig-
ure 3H revealed that MSI or MSS does not add additional discriminatory power for prediction of  clinical 
outcome on the basis of  RasGRP1 expression (Supplemental Figure 5C).
Last, we explored a fourth platform with a focus on metastatic CRC. We assessed RasGRP1 and SOS1 
expression levels, using primary CRC with patient-matched liver metastases from the MOSAIC (Multi-
center International Study of  Oxaliplatin/5FU-LV in the Adjuvant Treatment of  Colon Cancer with stage 
II and III CRC) study. Paired differential analysis revealed that RasGRP1 levels significantly decreased in 
liver metastases compared with primary tumors (Figure 3I, blue lines). By contrast, SOS1 expression levels 
were not significantly altered (Figure 3I, red and blue lines). In sum, expression levels of  RasGRP1 — but 
not of  SOS1 — decreased when CRC tumors became more aggressive, and RasGRP1 showed potential as 
a future prognostic marker for CRC clinical outcome in several platforms.
Murine CRC spheroids with less Rasgrp1 are more sensitive to anti-EGFR therapy. Given the challenge in 
identifying which individual patients will benefit most from anti-EGFR therapy and the clinical and finan-
cial implications thereof  in CRC, we explored whether RasGRP1 might be a valuable biomarker for the 
efficacy of  anti-EGFR therapy.
To first systematically test this idea, which was based on RasGRP1’s suppressive actions, we generated 
organoids from murine colonic tumors (termed spheroids herein) (Figure 4A). Spheroids from tumors found 
in the distal portion of  the colon of  ApcMin/+, ApcMin/+:Rasgrp1+/–, and ApcMin/+:Rasgrp1–/– mice were established 
with equal efficiency (data not shown) and manifested the stereotypic sphere appearance (Figure 4B). In 
agreement with increased Wnt signals when Apc function is perturbed (37), ApcMin/+ and ApcMin/+:Rasgrp1–/– 
spheroids proliferated spontaneously without addition of  R-spondin and Wnt surrogate ligands (Figure 4C).
EGFR signaling is known to critically contribute to ApcMin/+-driven pathology; a hypomorphic Egfrwa2 
allele crossed into ApcMin/+ results in a 90% reduction in intestinal polyps (49). Addition of  exogenous EGF 
to the Matrigel revealed that this growth factor drove proliferation in all spheroids, but more extensively 
in ApcMin/+:Rasgrp1–/– spheroids, which lack suppression by Rasgrp1 (Figure 4D). Furthermore, inclusion of  
erlotinib in the media in which the Matrigel droplet was submerged (Figure 4A) reduced the viability of  
ApcMin/+ spheroids in a dose-dependent manner, and the efficacy was greatest when 1 or 2 alleles of  Rasgrp1 
were absent (ApcMin/+:Rasgrp1–/– and ApcMin/+:Rasgrp1WT/–; Figure 4E). This platform of  CRC spheroids from 
well-defined genetically engineered mouse models reveals that anti-EGFR therapy was most effective when 
expression levels of  the suppressor Rasgrp1 were low or absent.
RasGRP1 is a marker that stratifies anti-EGFR therapy efficacy. Last, we collaborated with the Alliance for Clini-
cal Trials in Oncology and performed a retrospective analysis of CRC patients who were enrolled in the national 
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Figure 3. RasGRP1 is a prognostic marker for CRC. (A–C) RasGRP1 expression in human CRC patients from the TCGA Colorectal Adenocarcinoma data sets. 
Expression of RasGRP1 in patients with WT versus mutant APC (A), WT versus mutant TP53 (B), and WT versus mutant KRAS (C). Statistical analyses were 
performed using unpaired t test; *P < 0.05. (D) Analysis of relative RasGRP1 expression using TCGA data as in A–C, organized by number of mutations in APC, 
TP53, and KRAS. *P < 0.05 (Dunnett’s test). (E) Analysis of relative SOS1 expression using TCGA data as in B–D, organized by number of mutations in APC, TP53, 
and KRAS. (F) RasGRP1 mRNA expression determined by TaqMan PCR on liver metastasis samples surgically removed from 124 patients with metastatic CRC. 
KRASmut, n = 87; KRASWT, n = 37. (G) Imunohistochemistry for RasGRP1 (brown staining) on liver metastasis patient samples selected from G with either low or 
high RasGRP1 levels. Scale bars: 20 μm. (H) Kaplan-Meier overall survival curve for stage II and III PETACC-3 CRC patients (n = 282) carrying KRAS mutation, divid-
ed in 2 equal groups of 141 patients expressing high or low levels of RasGRP1 (*P = 0.02, log-rank [Mantel-Cox] test). (I) Analysis of RasGRP1 and SOS1 expression 
in matched primary and metastatic tumors from patients with metastatic CRC in the MOSAIC program. Gene expression levels (in log2 of RPKM) for RasGRP1 and 
SOS1 in metastases (red dots) were compared with levels in primary tumors (blue dots). Red lines and blue lines represent increase and decrease in expression 
level, respectively. Student’s t test was performed to assess the statistical significance between comparisons. *P < 0.05.
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CALGB 80203 trial of FOLFOX/FOLFIRI versus FOLFOX/FOLFIRI with the anti-EGFR blocking anti-
body cetuximab (7). Two hundred thirty-eight patients were enrolled in CALGB 80203 (Figure 5A, consort 
overview of the FOLFIRI and FOLFOX groups), and this is currently the only trial with data available for 
analysis. The follow-up CALGB 80405 trial is actively ongoing, and no data have been liberated as of the writ-
ing of this article. In addition, the CALGB 80405 trial compares cetuximab and/or bevacizumab (anti-VEGF 
therapy) together with combination chemotherapy, and there is no combination chemotherapy–alone arm. Alli-
ance-banked RNA from patients was tested for RasGRP1 mRNA levels by TaqMan, and RasGRP1 RNA levels 
could be reliably assayed in 84 patient tumors for which KRAS typing was available as well (Figure 5B).
TaqMan results revealed a range of  gradual values of  RasGRP1 mRNA expression levels (Figure 
5C), with distribution that approximated a Gaussian curve over 8 groups of  RasGRP1 expression levels 
(Figure 5D). Since the RasGRP1 mRNA expression levels in the midrange level were close, we next 
divided patient tumors into the 25% highest and 25% lowest RasGRP1 expression quartiles (Figures 5, 
C and D) and compared the clinical outcome between the patients receiving FOLFOX/FOLFIRI alone 
and FOLFOX/FOLFIRI in combination with cetuximab. We evaluated the distribution of  overall sur-
vival and RasGRP1 in patients with KRASWT tumors (52 patients). Patients with low tumor expression of  
RasGRP1 experienced prolonged survival when cetuximab was added to FOLFOX/FOLFIRI (median 
40.8 months vs. 20.0 months, P = 0.03) (Figure 5E). This effect was not observed in patients expressing 
high levels of  RasGRP1 (P = 0.85) (Figure 5F and Supplemental Figure 6). As CALGB 80203 was con-
ducted before KRAS testing became part of  standard of  care, we had available data for some KRASmut 
(n = 32) patients (Figure 5B). Our limited analysis of  patients with KRASmut tumors suggests that there 
was no benefit of  addition of  cetuximab to FOLFOX/FOLFIRI when CRC patients were stratified on 
the basis of  RasGRP1 expression (Supplemental Figure 5, B and C). It should be noted that we did not 
observe significant differences in patient survival when we divided patient tumors into the 50% highest 
and 50% lowest RasGRP1 expression halves (Figure 5, C and D, and data not shown).
In sum, the results of the murine CRC spheroid assays presented in Figure 4 and retrospective analysis of  
CALGB 80203 data are consistent with the notion that RasGRP1 is a tumor suppressor gene in colonic epitheli-
um with aberrant Wnt signaling; and is a marker of the EGFR pathway that has potential relevance in the clinic 
as both a prognostic and potential predictive factor for the efficacy of anti-EGFR therapy for CRC patients.
Discussion
Here we demonstrate that RasGRP1 is a tumor suppressor in colonic epithelium with aberrant Wnt signal-
ing that has value as a prognostic marker to monitor clinical progression of  CRC. Moreover, capitalizing 
on murine CRC spheroids and CRC patient data from the CALGB 80203 clinical trial, we uncover that 
RasGRP1 is a biomarker that could be relevant for predicting efficacy of  anti-EGFR therapy for CRC 
patients. It is of  interest to note that RasGRP1 itself  is activated by EGF/EGFR signals (32). This fea-
ture may make RasGRP1 particularly useful as a prognostic and as an accompanying biomarker, as the 
predictive potential is unambiguously coupled to EGFR signals and RasGRP1’s biology. Additional test-
ing in randomized trials of  EGFR-targeting agents should be considered to confirm tumor expression of  
RasGRP1 as a predictive biomarker.
Data mining of  5 bioinformatics platforms showed that a decrease in RasGRP1 expression correlated 
with tumor aggressiveness and poor clinical outcome in human CRC, whereas analysis of  SOS1 did not 
reveal any particular patterns. The parallels between Rasgrp1 and Lrig1 mentioned above are intriguing. 
Tet-induced expression of  the transmembrane molecule Lrig1 dampens EGFR signaling (42) and establish-
es balanced intestinal stem cell homeostasis (21). Analysis of  TCGA data sets (colorectal, lung, glioblas-
toma, and ovarian) revealed that the LRIG1 locus is rarely lost or mutated (50). Nevertheless, LRIG1 
expression analysis helps define the tumor type and stage in clear cell renal cell carcinoma (51), and low-lev-
el expression of  Lrig1 correlates with poor differentiation of  squamous cell carcinomas and worse clinical 
outcome (52). In breast cancer, high expression of  Lrig1 has been described in cells of  patients with the best 
clinical outcome, and high Lrig1 expression correlates with a greater chance for relapse-free survival (50). 
To date, little is known about regulation of  LRIG1 expression levels. We have not observed increases in 
RasGRP1 expression upon EGFR signaling (data not shown), implying that RasGRP1’s negative feedback 
on EGFR signaling is constant. LRIG1 as a marker in CRC is worthy of  future studies, possibly motivated 
by our present study showing that RasGRP1 expression declines when CRC progresses and becomes more 
aggressive. How RasGRP1 expression levels decrease or disappear needs to be explored in depth.
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Roughly 95% of pancreatic ductal carcinomas (PDACs) contain KRAS mutations, yet EGFR signaling 
still appears to be essential for KRASmut-driven PDACs in mice (53, 54), and in the clinic erlotinib is beneficial 
for some PDAC patients (55). These results in PDACs suggest that anti-EGFR therapy should perhaps not be 
totally discarded when tumors have RAS mutations. Organoid technology has revolutionized cell biological 
studies on stem cell compartments (15, 16) and is also starting to emerge as a versatile and reliable platform 
for therapy testing (56–58). We have employed organoids here combined with R-spondin and Wnt surrogate 
ligands, EGF growth factors, EGFR inhibitors, and genetic deletion of  Rasgrp1, since Rasgrp1 inhibitors are 
not available to date. How to overcome the difficulty of  targeting oncogenic RAS mutations is an ongoing 
challenge, but future organoid and spheroid assays — in the space of  the Matrigel droplet, which mimics a 3D 
tissue — should allow for multidimensional testing of  such parameters as RasGRP1 and LRIG1 expression 
levels and KRAS status, as well as multiple therapies, including but not limited to anti-EGFR.
Methods
Bioinformatics and TCGA data mining. For analysis of  RasGRP1 mRNA expression in correlation with APC, 
KRAS, and TP53 mutation statuses, TCGA Colorectal Adenocarcinoma database was obtained and ana-
lyzed with cbioPortal (http://www.cbioportal.org/), which is embedded in the TCGA database (https://
portal.gdc.cancer.gov/), as we previously described (30).
Figure 4. Deletion of Rasgrp1 alleles makes CRC spheroids susceptible to EGFR inhibition. (A) Scheme of murine CRC organoid generation from colonic 
tumors. (B) Representative images of CRC organoids from ApcMin/+, ApcMin/+:Rasgrp1WT/–, and ApcMin/+:Rasgrp1–/– colonic adenomas. Each image is a represen-
tative example of 40 or more wells of tumor spheroids; 8 wells per mouse tumor and 5 or more mice per genotype. Scale bars: 200 μm. (C and D) Murine 
ApcMin/+ CRC organoids and ApcMin/+:Rasgrp1–/– CRC organoids were incubated in plain growth media (C) or with exogenous EGF (50 ng/mL) (D). Prolifera-
tion rate was evaluated on days 1, 3, and 5 after plating. Data are mean ± SEM and were normalized to day 1. A total of 6 wells for each condition from 2 
independent experiments were evaluated (n = 3 ApcMin/+, n = 3 ApcMin/+:Rasgrp1–/– mice). ****P < 0.0001 (2-way ANOVA, Bonferroni’s multiple-comparisons 
test). (E) ApcMin/+ CRC organoids, ApcMin/+:Rasgrp1–/– CRC organoids, and ApcMin/+:Rasgrp1WT/– CRC organoids were treated with different doses of erlotinib for 
3 days. DMSO was used as control. All data were normalized to untreated conditions. A total of 4–5 independent experiments with 4 wells per condition 
(16–20 wells total) were evaluated. Each dot represents the average of 4 wells, columns indicate the mean, and bars represent the SD (n = 5 ApcMin/+, n = 4 
ApcMin/+:Rasgrp1–/– mice). *P < 0.05, **P < 0.01 (Dunnett’s test). 
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Figure 5. RasGRP1 as a biomarker marker for anti-EGFR therapy. (A) Consort overview of CALGB 80203 trial patients 
receiving the indicated therapy, provided by the Alliance for Clinical Trials in Oncology. (B) Scheme of CALG 80203 trial 
patients analyzed for RasGRP1 expression by TaqMan and organized on KRAS status. (C) RasGRP1 mRNA levels in 84 
patients in the CALGB 80203 clinical trial. Graph shows the quartile of patients with highest RasGRP1 expression in their 
tumors (RasGRP1 High), as well as the quartile of patients with lowest RasGRP1 expression in their tumors (RasGRP1 
Low). Groups were identified by calculating the average of Ct. Standard deviation (SEM) represents the value of repeat of 
same samples. (D) Patients were divided into 8 groups of stepwise, increasing Ct values. Nonlinear regression (curve fit) 
showing difference between high- and low-quartile patients. Blue bars represent quartile of patients with high expression 
of RasGRP1; red bars represent quartile of patients with low expression of RasGRP1. (E) Comparison of FOLFOX/FOLFIRI 
chemotherapy versus FOLFOX/FOLFIRI with cetuximab for the quartile of patients with lowest RasGRP1 expression in their 
tumors. Overall survival was graphed in a retrospective analysis of KRASWT CRC patients enrolled in the CALG 80203 trial. 
Median (med.) survival is indicated for the 2 groups in months; P = 0.03. (F) As in C, but the comparison between FOLFOX/
FOLFIRI (dashed lines) and FOLFOX/FOLFIRI with cetuximab (solid lines) is made for the quartile of patients with the 
highest RasGRP1 expression in their tumors. Median survival was calculated for each group in months; P = 0.85. Log-rank 
(Mantel-Cox) test was used for statistical analysis in E and F. 
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To evaluate the correlation with RasGRP1 expression in 18 normal colon, 20 primary colonic tumor, 
and 19 liver metastases, the GSE49355 data set (34) was downloaded from the NCBI Gene Expression 
Omnibus database. Gene expression values were normalized and annotated by GeneSpring GX 12 soft-
ware (Agilent Technologies). One-way ANOVA statistical analysis with Bonferroni’s corrections was car-
ried out by use of  SPSS 17.0.
For analysis of  RasGRP1 as a marker for survival of  metastatic CRC patients, we used data from the 
PETACC-3 clinical trial (ArrayExpress E-MTAB-990) (45). The PETACC-3 data set gathers 752 FFPE 
samples from CRC patients and is a randomized, multicenter, adjuvant therapy clinical trial that evaluated 
FU and LV alone or combined with irinotecan in curatively resected stage II and III colon cancer. To assess 
whether RasGRP1 expression level affects survival of  patients with metastatic CRC, we split metastatic 
CRC patients from PETACC-3 into 2 subgroups: one group of  patients with high expression of  RasGRP1; 
one group of  patients with low RasGRP1 expression. The threshold used to split the data was the median 
RasGRP1 expression value, an arbitrary value leading to an equal number of  patients in each subgroup. 
With the same strategy, we also assessed separately the effect of  RasGRP1 expression level on survival for 
KRASWT and KRASmut patients. Survival analyses were done with the R programming language (version 
3.3.1) using functions from the “survival” package. Survival curves were drawn following the Kaplan-Mei-
er method and compared via the log-rank test. A Cox regression model was fitted on the data in order to 
compute the hazard ratios between the 2 RasGRP1 groups.
For the MOSAIC study, RNA quality was assessed using an Agilent Bioanalyzer, and only the samples 
displaying acceptable RNA integrity number (RIN > 7) were kept for sequencing, corresponding to 42 
doublets (primary tumors + liver metastases), 8 triplets (normal colon + primary tumors + liver metasta-
ses), and 2 unmatched metastases. RNA-Seq libraries were prepared using Illumina TruSeq Stranded Total 
RNA reagents (catalog RS-122-2201; Illumina) according to the protocol provided by the manufacturer and 
400 ng total RNA. We used the Ribo-Zero Human kit (catalog MRZH11124; Illumina) in order to remove 
cytoplasmic ribosomal RNA. Cluster generation was performed with the libraries using Illumina HiSeq PE 
Cluster Kit v4 cBot reagents (catalog PE-401-400) and sequencing performed on the Illumina HiSeq 2500 
using HiSeq SBS Kit v4 reagents (catalog FC-401-4002). Sequencing data were processed using Illumina 
Pipeline Software version 1.84. The initial number of  reads averaged 123 ± 29 (mean ± SD) million per 
sample. Reads were first trimmed to remove poly(A) and Illumina TruSeq adapter sequences using cut-
adapt (59) and aligned to the human reference hGRC37 genome using the STAR aligner (60). The number 
of  counts was summarized at the gene level using featureCounts (61). Reads that uniquely mapped to the 
reference genome averaged 86% ± 14%. A non-negligible part of  the sequences (30.4% ± 13.8%) mapped 
to intronic regions and thus were filtered out for subsequent analyses. After filtering out of  intronic reads, 
the rate of  reads mapping to ribosomal RNA was 8.1% ± 15.7%, while 88.2% ± 4.1% mapped to exonic 
protein-coding sequences, corresponding to a final read number of  59 × 106 ± 19 × 106 reads per sample. 
Read counts were normalized into reads per kilobase per million (RPKM) and log2 transformed after addi-
tion of  a pseudocount value of  0.001. Two patients were excluded based on principal component analysis, 
which resulted in a final gene expression matrix of  14,112 genes and 96 samples (corresponding to primary 
tumors and paired liver metastases of  48 patients).
Antibodies and reagents. Antibodies were obtained from the following sources and used at indicated con-
centration: Sos1 (1:1000) from BD Biosciences (catalog 610095, clone 25/SOS1); EGFR (1:1000, catalog 
4267) and β-actin (1:1000; catalog 4970) from Cell Signaling Technology; murine Rasgrp1 (m199) (1:500), 
generated by our laboratory together with Epitomic. Matrigel Growth Factor Reduced (GFR) Basement 
Membrane Matrix (product 354230) from Corning. Erlotinib HCl (OSI-744) was from Selleck Chemicals.
Mice. ApcMin/+ mice were crossed to Rasgrp1–/– mice (provided by Jim Stone, University of  Alberta, 
Edmonton, Alberta, Canada) to generate mice expressing ApcMin/+ in the context of  deletion of  1 and 2 
Rasgrp1 alleles: ApcMin/+:Rasgrp1WT/– and ApcMin/+:Rasgrp1–/–, respectively (30). Rag-KO mice were provided 
by Averil Ma (UCSF). Primers used for genotyping of  Rasgrp1 and ApcMin were described previously (30).
CALGB 80203 sample collection and RNA isolation. FFPE baseline tumor samples were collected from 
patients participating in CALGB 80203 (62). RNA was extracted from an FFPE block of  primary colon or 
rectum tumor as previously described (63).
CALGB 80203 quantitative real-time PCR analysis. TaqMan quantitative PCR was performed for 
RasGRP1 using the StepOne Real Time PCR System (Applied Biosystems, Life Technologies). Rela-
tive amounts of  RasGRP1 mRNA expression were normalized to β-actin mRNA and expressed as ΔCT 
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= CT(RasGRP1) – CT(β-actin), where CT is the threshold cycle. The RasGRP1 and β-actin assays were 
performed as previously described (30). The TaqMan β-actin assay was Hs00357333_g1; the RasGRP1 
assay was Hs0096734_m1. All assays were performed in duplicate. Duplicate samples with CT SD > 0.5 
cycles and average CT < 35 were rerun for improved quantitative PCR reproducibility. The second run 
was used if  the SD was less than 0.5 cycles. Samples with a final SD > 0.7 cycles were excluded. A final 
total of  84 samples were used for this analysis.
Mouse organoids: preparation, culture, and imaging. Mouse (6–8 weeks old) colon was isolated and washed 
in cold PBS. Distal colon was cut longitudinally and into small pieces before being incubated in isolation 
buffer (PBS 3 mM EDTA) for 60 minutes, rotating at 4°C. Pieces were incubated in 20 mL cold buffer and 
shaken for 4 minutes. Suspension was collected, and the process was repeated until the suspension was 
clear (3–4 times). All suspensions were pooled, centrifuged at 500 g for 10 minutes at 4°C, and resuspended 
in cold PBS–10% FBS. After counting and centrifugation for 5 minutes, 700 g at 4°C, crypts were resus-
pended in Matrigel at a concentration of  200–500 crypts per 50 μL Matrigel drop. Murine organoids were 
cultured in media (adapted from ref. 43) DMEM/F12 with GlutaMAX (Gibco, Life Technologies), penicil-
lin/streptomycin (100 μg/mL), N-2 Supplement (1×), B27 Supplement minus Vitamin A (1×; Gibco, Life 
Technologies), HEPES (10 mM; UCSF Cell Culture Facility), Murine Recombinant Noggin (100 ng/mL; 
PeproTech), N-acetylcysteine (1 mM; Matrix Scientific), R-Spondin2 (25 nM), Wnt surrogate ligand (0.3 
nM; K. Christopher Garcia Laboratory, Stanford University, Stanford, California) (18) and supplemented 
or not with Murine Recombinant EGF (50 ng/mL; PeproTech). Images were taken on day 11 using a 
BZ-X700 inverted microscope with a CCD cooling camera and BZ-X analysis software (KEYENCE).
Mouse CRC organoids. Colon was dissected and flushed with cold PBS. Colonic adenomas were collect-
ed and incubated in cold PBS 5–10 minutes for gentle washing. As previously described (64), tumors were 
incubated in chelation buffer (2 mM EDTA [Corning], 5.6 mmol/L Na2HPO4, 8.0 mmol/L KH2PO4, 96.2 
mmol/L NaCl, 1.6 mmol/L KCl, 43.4 mmol/L sucrose, 54.9 mmol/L d-sorbitol, 0.5 mmol/L dl-dithioth-
reitol [Sigma-Aldrich] in distilled water) for 60 minutes on ice.  Chelation buffer was then washed with cold 
PBS, and tumors were cut in pieces; incubated in digestion buffer (2.5% FBS [Omega Scientific Inc.,], 1 U/
mL penicillin, 1 μg/mL streptomycin,  2.5 ng/mL amphotericin B [Sigma-Aldrich], 200 U/mL type IV col-
lagenase [Gibco, Life Technologies], 125 μg/mL type II dispase [Sigma-Aldrich] in DMEM) for 2 hours at 
37°C; and shaken regularly.  Cells were then filtered, counted, and seeded with Matrigel to up to 15,000 cells 
per 50-μL Matrigel drop. Culture media was then added to the well after 5–10 minutes of  polymerization at 
37°C. Murine spheroids were cultured in DMEM/F12 with GlutaMAX penicillin/streptomycin (100 μg/
mL), HEPES (10 mM), N-2 Supplement (1×), B27 Supplement minus Vitamin A (1X), N-acetylcysteine (1 
mM), and amphotericin B (2.5 ng/mL) and supplemented with murine recombinant EGF (50 ng/mL) (64).
RNA extraction and real-time PCR. Total RNA was isolated from human tissue using an RNeasy kit 
(QIAGEN). RNA was reverse transcribed with random primers (Invitrogen) and Moloney murine leu-
kemia virus reverse transcriptase. Mouse RNA extraction from intestinal epithelial cells was done using 
poly(DT) primers for reverse transcription. Real-time PCR was performed in triplicate using Eppendorf  
RealPlex2. Gene expression was normalized to GAPDH (human) or β-actin (mouse) and quantified with 
the comparative CT method according to the manufacturer’s instructions. Probes and primers for RasGRP1 
and GAPDH were obtained from Applied Biosystems.
Western blot analysis. Cells were lysed with ice-cold 1% NP-40 supplemented with protease and phos-
phatase inhibitors (10 mM sodium fluoride, 2 mM sodium orthovanadate, 0.5 mM EDTA, 2 mM phe-
nyl-methylsulfonyl fluoride, 1 mM sodium molybdate, aprotonin [10 mg.mL–1], leupeptin [10 mg.mL–1], 
pepstatin [1 mg.mL–1]). For colonic organoids, protein extraction was done in 2% NP40. After 30 minutes 
on ice, lysates were centrifuged, and supernatants were mix with 4× LDS sample buffer (Invitrogen). Pro-
tein lysates were separated on precast Tris-glycine gel 4%–12% (Invitrogen), transferred onto PVDF mem-
branes, and incubated with primary antibodies of  interest. Western blots were visualized with enhanced 
chemiluminescence and imaging on a Fuji LAS 4000 image station (GE Healthcare).
Extraction of  intestinal epithelial cells. Intestinal epithelial cells were isolated as previously described 
(65). Briefly, small intestine and colon of  mice (12–13 weeks old) were dissected, washed with cold 
PBS, and cut in three 2-cm pieces for small intestine — duodenum, jejunum and ileum; and two pieces 
for colon — proximal and distal. After cleaning, pieces were incubated on ice in 10 mL cold isolation 
buffer (2.7 mM KCl; 1 M KCl ; 150 mM NaCl; 1.2 mM KH
2
PO
4
; 680 mM Na
2
HPO
4;
 1.5 mM EDTA; 
0.5 mM DTT [added fresh] in 1 L ddH
2
O). After 15 minutes of  incubation, the suspension was dis-
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carded, and tissues were vortexed in 5 mL PBS. The suspension was collected in another tube, and 
isolation buffer was added to the tissue and incubated 15 minutes on ice. The process was repeated 3 
times. The suspension of  each repeat was pooled in the collecting tube and centrifuged at 1000 rpm, 
4°C for 10 minutes. Cells were resuspended in PBS and separated for protein extraction (2/3 of  sus-
pension) or RNA extraction (1/3 of  suspension).
Viability assays. Organoids were seeded in 96-well clear, flat-bottom plates in a mixture of  Matrigel and 
media for 24 hours at 37°C. Organoids were then incubated with increasing concentrations of  erlotinib 
with 4 wells per condition for 72 hours at 37°C. Viability of  organoids was evaluated using CellTiter-Glo 
3D as described by the manufacturer (Promega). Luminescence was read on a SpectraMax M5 (Molecular 
Devices). Values were normalized to those in untreated conditions after removal of  background.
Immunohistochemistry. Human tissues were collected, fixed in 4% PFA, and paraffin embedded. 
Then 5-μm-thick sections were dewaxed in Histo-Clear (National Diagnostics) and rehydrated in graded 
alcohol baths. Antigen retrieval was performed in a pressure cooker for 10 minutes in 10 mM sodium 
citrate buffer, pH 6.0. Endogenous peroxidase activity was inhibited with 1.5% H2O2 in methanol for 20 
minutes, and sections were washed in PBS. Nonspecific binding sites were blocked in blocking buffer 
(PBS, pH 7.4, 3% goat serum, 1% BSA, and 0.1% Tween) for 60 minutes at room temperature. Sections 
were then incubated with primary antibodies diluted in blocking buffer overnight at 4°C. Slides were 
then washed twice with 0.1% PBS-Tween before incubation in universal immunoperoxidase polymer 
anti-rabbit N-Histofine (Nichirei Biosciences), used as a secondary reagent. Stainings were visualized 
with DAB (Sigma-Aldrich), and hematoxylin counterstaining (Shandon Instant Hematoxylin) was per-
formed before dehydration. After dehydration, sections were mounted in Cytoseal 60 (Thermo Fisher 
Scientific). To study the structure of  tissue and cell types, H&E staining was performed. Images were 
acquired using Imager M2 microscope equipped with an AxioCam MRs (Zeiss).
Statistics. Pixel values were transformed into metric values using internal microscope scales. All data 
are represented as mean ± SEM. All specific statistical analyses and numbers of  repeats are provided in 
the respective figure legends. Unpaired t test was used to compare 2 groups in Figure 3, A–C, and Sup-
plemental Figure 6B. For all other experiments, with multiple comparisons, 1-way and 2-way ANOVA 
followed by a Bonferroni’s or Dunnett’s post hoc test were used for comparisons of  3 or more groups. 
Log-rank (Mantel-Cox) test was used for Kaplan-Meier survival curves. For all tests, a P value less than 
0.05 was considered statistically significant. Analyses and graphs were done using GraphPad Prism 6.
Study approval. Mice were handled according to UCSF Institutional Animal Care and Use Com-
mittee regulations, as approved in Roose laboratory mouse protocol AN084051, “Ras Signal Trans-
duction in Lymphocytes and Cancer.” Decoded CRC patient samples (UCSF samples) were obtained 
for TaqMan analysis of  RasGRP1 expression under approval of  the Committee on Human Research 
[CHR] as part of  approval study title “RasGRP1 in Human T Cell Lymphoma and Colorectal Cancer 
IRB 12-09467). RSW performed TaqMan analysis of  the UCSF CRC patient samples. CALGB 80203 
was approved by the Duke University Health System IRB under protocol ID Pro00018430, titled “Mark-
ers of  Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: A Correlative 
Sciences Study of  Tissues from CALGB Protocol 80203.” Patient and ethics approval for this study was 
obtained from the PETACC-3 Translational Research Working Party (PTRW). For the MOSAIC study, 
bulk RNA-Seq data previously generated by the Colorectal Cancer Metastases Working Group (Sabine 
Tejpar, unpublished) was examined to compare the expression of  RasGRP1 in primary colorectal carci-
nomas and their matched liver metastases in previously untreated patients. All tissue was collected under 
local IRB-approved tissue banking projects at 11 sites within Europe and the USA.
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